These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24935463)

  • 1. Does pregnancy alter the long-term course of multiple sclerosis?
    Karp I; Manganas A; Sylvestre MP; Ho A; Roger E; Duquette P
    Ann Epidemiol; 2014 Jul; 24(7):504-8.e2. PubMed ID: 24935463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
    Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
    Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
    Katz Sand I; Krieger S; Farrell C; Miller AE
    Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory dysfunction in multiple sclerosis: association with secondary progression.
    Silva AM; Santos E; Moreira I; Bettencourt A; Coutinho E; Gonçalves A; Pinto C; Montalban X; Cavaco S
    Mult Scler; 2012 May; 18(5):616-21. PubMed ID: 22020420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A non-parametric propensity score for estimating the effect of interferon-beta or glatiramer acetate on long-term outcomes of multiple sclerosis.
    Mésidor M; Sylvestre MP; Rousseau MC; Roger E; Duquette P
    Mult Scler Relat Disord; 2021 Aug; 53():103050. PubMed ID: 34116479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
    Trojano M; Paolicelli D; Bellacosa A; Cataldo S
    Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining reliable disability outcomes in multiple sclerosis.
    Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
    Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
    J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study.
    Casanova B; Coret F; Valero C; Landete L; Pascual A; Vilchez JJ
    Mult Scler; 2002 Feb; 8(1):59-63. PubMed ID: 11939173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
    Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
    Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.